1. Center for Innovation in Regulatory Science. Measuring benefit and balancing risk: strategies for the benefit-risk assessment of new medicines in a risk-averse environment. http://www.cirsci.org/sites/default/files/June_2008.pdf. Published 2008. Accessed November 20, 2013.
2. Leong J, McAuslane N, Walker S, Salek S. Is there a need for a universal benefit-risk assessment framework for medicines? Regulatory and industry perspectives. Pharmacoepidemiol Drug Saf. 2013;22:1004–1012.
3. European Medicines Agency. Reflection paper on benefit-risk assessment methods in the context of the evaluation of marketing authorization applications of medicinal products for human use. http://www.ema.europa.eu/docs/en_GB/document_library/Regulatory_and_procedural_guideline/2010/01/WC500069634.pdf. Published 2008. Accessed November 20, 2013.
4. European Medicines Agency. Benefit-risk methodology project: development and testing of tools and processes for balancing multiple benefits and risks as an aid to informed regulatory decisions about medicinal products. http://www.ema.europa.eu/docs/en_GB/document_library/Report/2011/07/WC500109477.pdf. Published 2009. Accessed November 20, 2013.
5. European Medicines Agency. Benefit-risk methodology project: work package 2 report. Applicability of current tools and processes for regulatory benefit-risk assessment. http://www.ema.europa.eu/docs/en_GB/document_library/Report/2010/10/WC500097750.pdf. Published 2010. Accessed November 20, 2013.